Clinical trial

HB-302/HB-301 Therapy in Participants With Metastatic Castration-Resistant Prostate Cancer

NCT05553639

Study summary

ClinicalTrials.gov

HB-302/HB-301 Therapy in Participants With Metastatic Castration-Resistant Prostate Cancer

Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE1, PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

BIOLOGICAL · Unmapped registry intervention HB-302/HB-301 Alternating 2-Vector Therapy Find medicine records · Find other trials using this name

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2023-05-23

PhasePHASE1 / PHASE2

Conditions

Prostate Cancer Metastaticverified · MONDO: metastatic prostate carcinoma

Interventions

HB-302/HB-301 Alternating 2-Vector TherapyBIOLOGICAL

Sponsors & collaborators

Hookipa Biotech GmbHlead sponsor

Mapped research locations

New YorkNew York, United States2 MiamiFlorida, United States2 AtlantaGeorgia, United States1 PortlandOregon, United States1 KnoxvilleTennessee, United States1 DuarteCalifornia, United States1 New BrunswickNew Jersey, United States1 San MarcosCalifornia, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05553639 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.